Opening the book…
Information in this section is derived or extracted from government publications in the public domain.
As part of the Unites States vaccine effort, on May 15, 2020, the federal government announced Operation Warp Speed (OWS).[8]
Goal/Mission
Operation Warp Speed’s goal was to produce and deliver 300 million doses of safe and effective vaccines with the initial doses available by January 2021, as part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (collectively known as countermeasures).[2]
The US government expressed its commitment to providing free or low-cost COVID-19 countermeasures to the American people as fast as possible. Any vaccine or therapeutic doses purchased with US taxpayer dollars would be given to the American people at no cost.[6, page 4]
Leadership
HHS Secretary Alex Azar and Defense Secretary Mark Esper provided oversight of OWS, with Dr. Moncef Slaoui designated as chief advisor and General Gustave F. Perna confirmed as the chief operating officer.[6]
Funding
On March 27, 2020, the United States Congress passed the CARES Act (Coronavirus Aid, Relief, and Economic Security), which initially provided about $10 billion in funding for Operation Warp Speed.[5]
Congress directed almost $10 billion to this effort through supplemental funding, including the CARES Act. Congress has also appropriated other flexible funding. The almost $10 billion specifically directed includes more than $6.5 billion designated for countermeasure development through BARDA and $3 billion for NIH research.[6, page 5]
Funding was increased to about $18 billion by October 2020.[9]
Constituency
Operation Warp Speed was a public–private partnership, initiated by the federal government of the United States, to facilitate and accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.[1]
Operation Warp Speed was a partnership among components of the Department of Health and Human Services (HHS), including the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), and the Department of Defense (DoD). OWS engaged with private firms and other federal agencies, including the Department of Agriculture, the Department of Energy, and the Department of Veterans Affairs. OWS coordinated existing HHS-wide efforts, including the NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership, NIH’s Rapid Acceleration of Diagnostics (RADx) initiative, and work by BARDA.[6, page 1]
Operation Warp Speed agencies:[6]
- Department of Health and Human Services (HHS), including the
- Centers for Disease Control and Prevention (CDC)
- Food and Drug Administration (FDA)
- National Institutes of Health (NIH), and
- Biomedical Advanced Research and Development Authority (BARDA)
- Department of Defense
- Other federal agencies, including the Department of Agriculture, the Department of Energy, and the Department of Veterans Affairs.
Private Companies Involved
- “As of July, eight companies had been chosen for funding to expedite development and preparation for manufacturing their respective vaccine candidates: Johnson & Johnson (Janssen Pharmaceutical), AstraZeneca-University of Oxford, Pfizer-BioNTech, Moderna, Merck, Vaxart, Inovio, and Novavax. In June agreements of $1.2 billion for successful vaccine were signed with AstraZeneca and $483 million with Moderna.”[4]
- “In July, Operation Warp Speed agreed to pay $1.6 billion to Novavax if clinical trials are successful to produce 100 million doses of its candidate vaccine. Novavax is a company with no history of marketed products. Also in July, Pfizer and BioNTech received an order of $2 billion to manufacture 100 million doses of a COVID-19 vaccine when it is shown to be safe and effective, and is licensed. On July 31st, Sanofi and GSK were funded for $2.1 billion.”[4]
Managing Vaccine Development
To accelerate development while maintaining standards for safety and efficacy, Operation Warp Speed selected the most promising countermeasure candidates and provided coordinated government support.
Protocols for the demonstration of safety and efficacy were aligned, allowing these harmonized clinical trials to proceed more quickly, and the protocols for the trials will be overseen by the federal government (NIH), as opposed to traditional public-private partnerships, in which pharmaceutical companies decide on their own protocols.
Rather than eliminating steps from traditional development timelines, steps will proceed simultaneously, such as starting manufacturing of vaccines and therapeutics at industrial scale well before the demonstration of efficacy and safety as happens normally. This increases the financial risk, but not the product risk.[6, page 1]
The bolding of some text in this section is to emphasize project management schedule acceleration techniques as an aid to the student.
The COVID-19 vaccine development plan was roughly:[6]
- Fourteen promising candidates were chosen from the 100+ vaccine candidates currently in development, some of them already in clinical trials with U.S. government support.
- The 14 vaccine candidates were narrowed down to about seven candidates, representing the most promising candidates from a range of technology options (nucleic acid, viral vector, protein subunit), which will go through further testing in early-stage clinical trials.
- Large-scale randomized trials for the demonstration of safety and efficacy proceeded for the most promising candidates.
Disbursements for Development[6]
Select actions to support Operation Warp Speed vaccine and therapeutic development included:[6]
- March 30: HHS announced $456 million in funds for Johnson & Johnson’s (Janssen) candidate vaccine. Phase 1 clinical trials began in Belgium on July 24th and in the U.S on July 27th.
- April 16: HHS made up to $483 million in support available for Moderna’s candidate vaccine, which began Phase 1 trials on March 16 and received a fast-track designation from FDA. This agreement was expanded on July 26 to include an additional $472 million to support late-stage clinical development, including the expanded Phase 3 study of the company’s mRNA vaccine, which began on July 27th.
- May 21: HHS announced up to $1.2 billion in support for AstraZeneca’s candidate vaccine, developed in conjunction with the University of Oxford. The agreement is to make available at least 300 million doses of the vaccine for the United States, with the first doses delivered as early as October 2020 and Phase 3 clinical studies beginning this summer with approximately 30,000 volunteers in the United States.
- July 7: HHS announced $450 million in funds to support the large-scale manufacturing of Regeneron’s COVID-19 investigational anti-viral antibody treatment, REGN-COV2. This agreement is the first of a number of OWS awards to support potential therapeutics all the way through to manufacturing. As part of the manufacturing demonstration project, doses of the medicine will be packaged and ready to ship immediately if clinical trials are successful and FDA grants EUA or licensure.
- July 7: HHS announced $1.6 billion in funds to support the large-scale manufacturing of Novavax’s vaccine candidate. By funding Novavax’s manufacturing effort, the federal government will own the 100 million doses expected to result from the demonstration project.
- July 22: HHS announced up to $1.95 billion in funds to Pfizer for the large-scale manufacturing and nationwide distribution of 100 million doses of their vaccine candidate. The federal government will own the 100 million doses of vaccine initially produced as a result of this agreement, and Pfizer will deliver the doses in the United States if the product successfully receives FDA EUA or licensure, as outlined in FDA guidance, after completing demonstration of safety and efficacy in a large Phase 3 clinical trial, which began July 27th.
- July 31: HHS announced approximately $2 billion in funds to support the advanced development, including clinical trials and large scale manufacturing, of Sanofi and GlaxoSmithKline’s (GSK) investigational adjuvanted vaccine. By funding the manufacturing effort, the federal government will own the approximately 100 million doses expected to result from the demonstration project. The adjuvanted vaccine doses could be used in clinical trials or, if the FDA authorizes use, as outlined in agency guidance, the doses would be distributed as part of a COVID-19 vaccination campaign.
- August 5: HHS announced approximately $1 billion in funds to support the large-scale manufacturing and delivery of Johnson & Johnson’s (Janssen) investigational vaccine candidate. Under the terms of the agreement, the U.S. Government will own the resulting 100 million doses of vaccine, and will have the option to acquire more. The company’s investigational vaccine relies on Janssen’s recombinant adenovirus technology, AdVac, a technology used to develop and manufacture Janssen’s Ebola vaccine with BARDA support; that vaccine received European Commission approval and was used in the Democratic Republic of the Congo (DRC) and Rwanda during the 2018-2020 Ebola outbreak that began in the DRC.
- August 11: HHS announced up to $1.5 billion in funds to support the large-scale manufacturing and delivery of Moderna’s investigational vaccine candidate. Under the terms of the agreement, the U.S. Government will own the resulting 100 million doses of vaccine, and will have the option to acquire more. The vaccine, called mRNA-1273, has been co-developed by Moderna and scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. NIAID has continued to support the vaccine’s development including nonclinical studies and clinical trials. Additionally, BARDA has supported phase 2/3 clinical trials, vaccine manufacturing scale up and other development activities for this vaccine. The Phase 3 clinical trial, which began July 27, is the first government-funded Phase 3 clinical trial for a COVID-19 vaccine in the United States.
Manufacturing[6]
The United States federal government made investments in the necessary manufacturing capacity at its own risk, giving private pharmaceutical firms the confidence to invest aggressively in development, facilitating faster distribution of an eventual vaccine.
The plan was to proceed with ramping up Manufacturing capacity for selected candidates while they were still in development, rather than scaling up after approval or authorization.
Actions to support Operation Warp Speed manufacturing efforts included:
- The May 21, April 16, and March 30 HHS agreements with AstraZeneca, Moderna, and Johnson & Johnson respectively include investments in manufacturing capabilities.
- June 1: HHS announced a task order with Emergent BioSolutions to advance domestic manufacturing capabilities and capacity for a potential COVID-19 vaccine as well as therapeutics, worth approximately $628 million, using Emergent’s BARDA-supported Center for Innovation in Advanced Department and Manufacturing.
- July 27: HHS announced a task order with Texas A&M University and FUJIFILM to advance domestic manufacturing capabilities and capacity for a potential COVID-19 vaccine, worth approximately $265 million, using another BARDA-supported CIADM.
- August 4: Grand River Aseptic Manufacturing Inc., (GRAM) Grand Rapids, Michigan, was awarded a $160 million firm-fixed-price contract for domestic aseptic fill and finish manufacturing capacity for critical vaccines and therapeutics in response to the COVID-19 pandemic.
Distribution[6]
Before the countermeasures were approved or authorized, the program built the necessary plans and infrastructure for distribution.
HHS planned for a tiered approach to vaccine and therapeutic distribution, which built on allocation methodology developed as part of pandemic flu planning and was adjusted based on experience from the COVID-19 response, data on the virus and its impact on populations, and the performance of a given countermeasure, and the needs of the essential workforce. Operation Warp Speed expanded domestic manufacturing and supplies of specialized materials and resources, such as glass vials, that can be necessary for distribution. DoD’s involvement enabled faster distribution and administration than would have otherwise been possible.
Select actions to support Operation Warp Speed distribution efforts include:
- May 12: DoD and HHS announced a $138 million contract with ApiJect for more than 100 million prefilled syringes for distribution across the United States by year-end 2020, as well as the development of manufacturing capacity for the ultimate production goal of over 500 million prefilled syringes in 2021.
- June 9: HHS and DoD announced a joint effort to increase domestic manufacturing capacity for vials that may be needed for vaccines and treatments.
- June 11: HHS announced $204 million in funds to Corning to expand the domestic manufacturing capacity to produce approximately 164 million Valor Glass vials per year if needed. Valor Glass provides chemical durability to minimize particulate contamination. The specialized glass allows for rapid filling and capping methods that can increase manufacturing throughput by as much as 50 percent compared with conventional filling lines, which in turn can reduce the overall manufacturing time for vaccines and therapies.
- June 11: HHS announced $143 million to SiO2 Materials Science to ramp up capacity to produce the company’s glass-coated plastic container, which can be used for drugs and vaccines. The new lines provide the capacity to produce an additional 120 million vials per year if needed.
Government Accountability Office report[7]
Operation Warp Speed was a federal effort that supported multiple COVID-19 vaccine candidates to speed up development.
The General Accountability Office (GAO) analyzed the program's vaccine candidates and found that their development followed traditional practices, with some adaptations. For example, some clinical trial phases overlapped with each other and with animal studies to accelerate development. Two vaccines were authorized for emergency use.
The GAO found that agencies were working to help mitigate vaccine manufacturing challenges. For example, agencies have taken steps to require contractors to prioritize vaccine production supplies.
Operation Warp Speed (OWS) aimed to help accelerate the development of a COVID-19 vaccine. GAO found that OWS and vaccine companies adopted several strategies to accelerate vaccine development and mitigate risk. For example, OWS selected vaccine candidates that use different mechanisms to stimulate an immune response (i.e., platform technologies). Vaccine companies also took steps, such as starting large-scale manufacturing during clinical trials and combining clinical trial phases or running them concurrently. Clinical trials gather data on safety and efficacy, with more participants in each successive phase (e.g., phase 3 has more participants than phase 2).
As of January 30, 2021, five of the six Operation Warp Speed vaccine candidates had entered phase 3 clinical trials, two of which (Moderna's and Pfizer/BioNTech's vaccines) received an emergency use authorization (EUA) from the Food and Drug Administration (FDA). For vaccines that received EUA, additional data on vaccine effectiveness will be generated from further follow-up of participants in clinical trials already underway before the EUA was issued.
Technology readiness
GAO's analysis of the Operation Warp Speed vaccine candidates' technology readiness levels (TRL), an indicator of technology maturity, showed that COVID-19 vaccine development under OWS generally followed traditional practices, with some adaptations. FDA issued specific guidance that identified ways that vaccine development may be accelerated during the pandemic. Vaccine companies told GAO that the primary difference from a non-pandemic environment was the compressed timelines. To meet OWS timelines, some vaccine companies relied on data from other vaccines using the same platforms, where available, or conducted certain animal studies at the same time as clinical trials. However, as is done in a non-pandemic environment, all vaccine companies gathered initial safety and antibody response data with a small number of participants before proceeding into large-scale human studies (e.g., phase 3 clinical trials). The two EUAs issued in December 2020 were based on analyses of clinical trial participants and showed about 95 percent efficacy for each vaccine. These analyses included assessments of efficacy after individuals were given two doses of vaccine and after they were monitored for about 2 months for adverse events.
Manufacturing
As of January 2021, five of the six Operation Warp Speed vaccine companies had started commercial scale manufacturing. OWS officials reported that as of January 31, 2021, companies had released 63.7 million doses—about 32 percent of the 200 million doses that, according to OWS, companies with EUAs have been contracted to provide by March 31, 2021. Vaccine companies face a number of challenges in scaling up manufacturing to produce hundreds of millions of doses under OWS's accelerated timelines. DOD and HHS worked with vaccine companies to help mitigate manufacturing challenges, including:
- Limited manufacturing capacity: A shortage of facilities with capacity to handle the vaccine manufacturing needs can lead to production bottlenecks. Vaccine companies worked in partnership with OWS to expand production capacity. For example, one vaccine company told GAO that HHS's Biomedical Advanced Research and Development Authority helped them identify an additional manufacturing partner to increase production. Additionally, the U.S. Army Corps of Engineers oversaw construction projects to expand capacity at vaccine manufacturing facilities.
- Disruptions to manufacturing supply chains: Vaccine manufacturing supply chains have been strained by the global demand for certain goods and workforce disruptions caused by the global pandemic. For example, representatives from one facility manufacturing COVID-19 vaccines stated that they experienced challenges obtaining materials, including reagents and certain chemicals. They also said that due to global demand, they waited 4 to 12 weeks for items that before the pandemic were typically available for shipment within one week. Vaccine companies and DOD and HHS officials told GAO they have undertaken several efforts to address possible manufacturing disruptions and mitigate supply chain challenges. These efforts included federal assistance to (1) expedite procurement and delivery of critical manufacturing equipment, (2) develop a list of critical supplies that are common across the six OWS vaccine candidates, and (3) expedite the delivery of necessary equipment and goods coming into the United States. Additionally, DOD and HHS officials said that as of December 2020 they had placed prioritized ratings on 18 supply contracts for vaccine companies under the Defense Production Act, which allows federal agencies with delegated authority to require contractors to prioritize those contracts for supplies needed for vaccine production.
- Gaps in the available workforce: Hiring and training personnel with the specialized skills needed to run vaccine manufacturing processes can be challenging. OWS officials stated that they have worked with the Department of State to expedite visa approval for key technical personnel, including technicians and engineers to assist with installing, testing, and certifying critical equipment manufactured overseas. OWS officials also stated that they requested that 16 DOD personnel be detailed to serve as quality control staff at two vaccine manufacturing sites until the organizations can hire the required personnel.
Why the Government Accountability Office Did This Study
As of February 5, 2021, the U.S. had over 26 million cumulative reported cases of COVID-19 and about 449,020 reported deaths, according to the Centers for Disease Control and Prevention. The country also continued to experience serious economic repercussions, with the unemployment rate and number of unemployed in January 2021 at nearly twice their pre-pandemic levels in February 2020.
In May 2020, Operation Warp Speed was launched and included a goal of producing 300 million doses of safe and effective COVID-19 vaccines with initial doses available by January 2021. Although FDA has authorized two vaccines for emergency use, Operation Warp Speed has not yet met its production goal by January 2021. Such vaccines are crucial to mitigate the public health and economic impacts of the pandemic.
GAO was asked to review Operation Warp Speed vaccine development efforts. This GAO report examined:
- the characteristics and status of the Operation Warp Speed vaccines,
- how developmental processes have been adapted to meet Operation Warp Speed timelines, and
- the challenges that companies have faced with scaling up manufacturing and the steps they are taking to address those challenges.
GAO administered a questionnaire based on HHS's medical countermeasures TRL criteria to the six Operation Warp Speed vaccine companies to evaluate the COVID-19 vaccine development processes. GAO also collected and reviewed supporting documentation on vaccine development and conducted interviews with representatives from each of the companies on vaccine development and manufacturing.
Figure \(\PageIndex{2}\): Traditional Vaccine Development Timeline Compared To Potential Operation Warp Speed Timeline. (Public Domain; General Accountability Office.[8, page 3])
Note: The timelines for vaccine development depicted in Figure \(\PageIndex{2}\) are not drawn to scale. These timelines depict examples, and the specific development steps and timelines for a given vaccine may vary from this example.
Figure \(\PageIndex{2}\) depicts a generic traditional vaccine timeline at the top and a potential Operation Warp Speed timeline on the bottom:
- Traditional Vaccine timeline: A serial timeline with approximately 10 years spanning Exploratory (depicted by laboratory flasks), Pre-clinical (depicted by a laboratory rat), and Clinical Trials Phases 1-3 (Phase 1 showing a small number of figures denoting people, Phase 2 showing a medium number of people, and Phase 3 with a large number of people), followed by large-scale manufacturing (stylized figure of vaccine manufacturing), and FDA Review and Licensure (depicted by a magnifying glass over a document).
- Potential Operation Warp Speed Timeline: A compressed timeline of approximately 10 months labeled by a demarcation at the bottom of the figure spanning Exploratory and Pre-clinical (depicted by a flask and laboratory rat), followed by Clinical Trials Phases 1, 2, and part of 3 (Phase 1 showing a small number of figures denoting people, Phase 2 showing a medium number of people, and Phase 3 with a large number of people), but with an arrow pointing to a box showing the potential for FDA Authorization for Emergency use before the conclusion of Phase 3, and with large-scale manufacturing (stylized figure of multi-station vaccine manufacturing with an arrow going to FDA Review and Licensure) overlapping the clinical trials. This is followed by FDA Review and Licensure (depicted by a magnifying glass over a document).
Footnote details
The footnotes from Figure \(\PageIndex{2}\) are:
- Footnote a:
- Phase 1 clinical trials generally test the safety of a product with a small group of healthy volunteers (usually fewer than 100). These trials are designed to determine the product’s initial safety profile and the side effects associated with increasing doses, among other things.
- Phase 2 clinical trials are designed to evaluate the effectiveness of a product for a particular use and determine the common short-term side effects and risks associated with the product. These trials are conducted with a medium-size population of volunteers (usually a few dozen to hundreds).
- Phase 3 clinical trials are performed after preliminary evidence suggesting effectiveness of a product has been obtained, and are intended to gather additional information about safety and effectiveness. These trials usually involve several hundred to thousands of volunteers, including participants who are at increased risk for infection. According to Food and Drug Administration (FDA) officials, these clinical trial phases may overlap.
- Footnote b:
- According to FDA, manufacturing processes are reviewed as part of the vaccine licensure process. Thus, even under a traditional vaccine timeline, some initial manufacturing occurs during development, so the manufacturing processes can be adequately validated. According to an OWS fact sheet, in some cases, the federal government is taking on the financial risk to enable large-scale manufacturing to start while clinical trials are ongoing, with the goal of having millions of doses available for distribution upon authorization or licensure of a COVID-19 vaccine.
- Footnote c:
- The Operation Warp Speed timeline depicts an example of a potential accelerated timeline for COVID-19 vaccine development. However, the development process of any given OWS vaccine candidate may vary from this example. As of January 2021, approximately 12 months have elapsed since exploratory and preclinical research began in January 2020, after the first U.S. cases of COVID-19 were reported. The timing for any remaining steps have yet to be determined as of this report. According to OWS documentation, certain steps may overlap or be shortened to accelerate the development of a COVID-19 vaccine.
- Footnote d:
- During an emergency, as declared by the Secretary of Health and Human Services under 21 U.S.C. § 360bbb-3(b), FDA may temporarily authorize unapproved medical products or unapproved uses of approved medical products through an emergency use authorization (EUA), provided certain statutory criteria are met. FDA has indicated that issuance of an EUA for a COVID-19 vaccine for which there is adequate manufacturing information would require the submission of certain clinical trial information from phase 3 clinical trials that demonstrate the safety and effectiveness of the vaccine in a clear and compelling manner, among other things. Any COVID-19 vaccine that initially receives an EUA from FDA is expected to ultimately be reviewed and receive licensure through a biologics license application, according to FDA guidance.
Technology Readiness Levels and Vaccine Development
Figure \(\PageIndex{3}\): Department of Health and Human Services' Integrated Technology Readiness Level (TRL) Countermeasure Scale and the Traditional Vaccine Development and Manufacturing Process. ([8,page 10])
Figure \(\PageIndex{3}\) depicts the mapping of the vaccine development process and manufacturing process to Technology Readiness Levels (TRLs).
Department of Health and Human Services' Integrated Technology Readiness Level (TRL) Countermeasure Scale and the Traditional Vaccine Development and Manufacturing Process
- Vaccine development process: A serial timeline with with a horizontal bar representing Exploratory/Pre-clinical (TRLs 1 through 5), followed by a horizontal bar representing Clinical Trials Phases 1 (TRL 6), Phase 2 (TRL 7), and Phase 3 (TRL 8A), followed by a horizontal bar representing submission of the BLA (biologics license application) (TRL 8B), followed by a horizontal bar representing FDA Review and Licensure (TRL 8C), and followed by a horizontal bar representing Post-Licensure (TRL 9).
- Manufacturing process: shows a horizontal bar representing lab scale quantities (TRL 4), followed by a horizontal bar representing "Develop process for non-CGMP small-scale manufacturing" (TRL 5), in parallel with the end of Exploratory/Pre-clinical in the Vaccine development process. This is followed by a horizontal bar representing "Manufacturing of CGMP-compliant product suitable for clinical trials":, overlapped with Clinical Trials Phase 1 (TRL 6). This is followed by by a horizontal bar representing "Initiate CGMP-compliant manufacturing at scale compatible with federal requirements and complete validation, consistency testing, and stability studies", covering Clinical Trials Phases 2 and 3, Submit BLA, and FDA Review and Licensure, covered by TRL 7, TRL 8A, TRL 8B, and TRL 8C.
- Technology Readiness Levels: Horizontal bars for each of the following: TRL 1, TRL 2, TRL 3, TRL 4, TRL 5, TRL 6, TRL 7, TRL 8A, TRL 8B, TRL 8C, and TRL 9. The mapping to the Vaccine development process and Manufacturing process is described above. Technology Readiness Levels (TRLs) in drug and vaccine development range from basic research (TRL 1) to regulatory approval and market launch (TRL 9). The TRLs provide a framework for assessing the maturity of a drug or vaccine candidate.
References
- Wikipedia - Operation Warp Speed. August 24, 2020.
- HHS Operation Warp Speed. U.S. Department of Health and Human Services. Explaining Operation Warp Speed. Accessed August 24, 2020.
- Wikipedia - Operation Warp Speed. August 23, 2020.
- Wikipedia - Operation Warp Speed. August 24, 2020.
- History of Operation Warp Speed. Accessed February 1, 2026.
- HHS Operation Warp Speed. U.S. Department of Health and Human Services. Explaining Operation Warp Speed. Accessed February 1, 2026.
- GAO-21-319. United States Government Accountability Office. OPERATION WARP SPEED Accelerated COVID 19 Vaccine Development Status and Efforts to Address Manufacturing Challenges. Publication number GAO-21-319. February 2021. Accessed February 1, 2026.
- GAO-21-319. United States Government Accountability Office. OPERATION WARP SPEED Accelerated COVID 19 Vaccine Development Status and Efforts to Address Manufacturing Challenges. Publication number GAO-21-319. February 2021. Accessed February 1, 2026.
- Wikipedia - Operation Warp Speed. Accessed February 2, 2026.
- Operation Warp Speed seal. U.S. Department of Defense. This file is a work of a U.S. military or Department of Defense employee, taken or made as part of that person's official duties. As a work of the U.S. federal government, the file is in the public domain in the United States.
2.2: Operation Warp Speed is shared under a CC BY 4.0 license and was authored, remixed, and/or curated by LibreTexts.
The book could not be loaded just now.